Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer

被引：1
|
作者：
Atkins, CD
机构：
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 1998年 / 90卷 / 06期
关键词：
D O I：
10.1093/jnci/90.6.468
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：468 / 468
页数：1
相关论文
共 50 条
  • [21] Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer
    Jakesz, R
    Hausmaninger, H
    Haider, K
    Kubista, E
    Samonigg, H
    Gnant, M
    Manfreda, D
    Tschurtschenthaler, G
    Kolb, R
    Stierer, M
    Fridrik, M
    Mlineritsch, B
    Steindorfer, P
    Mittlböck, M
    Steger, G
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) : 1701 - 1709
  • [22] The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer
    Rizki, Hirah
    Hillyar, Christopher
    Abbassi, Omar
    Miles-Dua, Sascha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (03)
  • [23] Relationship of body mass index to outcomes after lymph node-negative, estrogen receptor positive breast cancer.
    Dignam, JJ
    Johnson, KA
    Xu, L
    Rockette, HE
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 259 - 259
  • [24] Health economic impact of breast cancer index (BCI) for late disease management in patients with estrogen receptor-positive, node-negative breast cancer
    Gustavsen, G.
    Schroeder, B. E.
    Kennedy, P.
    Pothier, K.
    Erlander, M. G.
    Schnabel, C. A.
    CANCER RESEARCH, 2013, 73
  • [25] Conversion to node-negative after neoadjuvant chemotherapy is a surrogate prognostic marker in patients with hormone receptor-positive breast cancer
    Takahashi, Y.
    Hayashi, N.
    Matsuda, N.
    Kajiura, Y.
    Yoshida, A.
    Yagata, H.
    Nakamura, S.
    Suzuki, K.
    Tsunoda, H.
    Yamauchi, H.
    CANCER RESEARCH, 2013, 73
  • [26] Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer (Reprinted from vol 24, pg 3726, 2006)
    Paik, Soonmyung
    Tang, Gong
    Shak, Steven
    Kim, Chungyeul
    Baker, Joffre
    Kim, Wanseop
    Cronin, Maureen
    Baehner, Frederick L.
    Watson, Drew
    Bryant, John
    Costantino, Joseph P.
    Geyer Jr, Charles E.
    Wickerham, D. Lawrence
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (20) : 3565 - 3575
  • [27] Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor-Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical Factors
    Tang, Gong
    Cuzick, Jack
    Costantino, Joseph P.
    Dowsett, Mitch
    Forbes, John F.
    Crager, Michael
    Mamounas, Eleftherios P.
    Shak, Steven
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (33) : 4365 - 4372
  • [28] Multicenter retrospective study on the use of Curebest™ 95GC Breast for estrogen receptor-positive and node-negative early breast cancer
    Tsukamoto, Fumine
    Arihiro, Koji
    Takahashi, Mina
    Ito, Ken-ichi
    Ohsumi, Shozo
    Takashima, Seiki
    Oba, Takaaki
    Yoshida, Masayuki
    Kishi, Kazuki
    Yamagishi, Keisuke
    Kinoshita, Takayuki
    BMC CANCER, 2021, 21 (01)
  • [29] Multicenter retrospective study on the use of Curebest™ 95GC Breast for estrogen receptor-positive and node-negative early breast cancer
    Fumine Tsukamoto
    Koji Arihiro
    Mina Takahashi
    Ken-ichi Ito
    Shozo Ohsumi
    Seiki Takashima
    Takaaki Oba
    Masayuki Yoshida
    Kazuki Kishi
    Keisuke Yamagishi
    Takayuki Kinoshita
    BMC Cancer, 21
  • [30] LUMBAR SPINE BMD CHANGES FOLLOWING CHEMOTHERAPY IN WOMEN WITH ESTROGEN RECEPTOR-POSITIVE BREAST CANCER AND LYMPH NODE INVOLVEMENT
    Loriggiola, Laura
    Lumachi, Franco
    Camozzi, Valentina
    Chiara, Giordano Bruno
    Basso, Stefano Maria Massimiliano
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 : S195 - S196
12345